| Methods |
Randomized, double‐blind, placebo‐controlled.
Weight loss trial. |
| Participants |
339 patients with one or more cardiovascular risk factor(s). 1 year follow‐up. Mean age 52 y. Mean BMI 37.8 kg/m2. Mean weight 108 kg. Australia and New Zealand. |
| Interventions |
Orlistat 120 mg tid (n=170). Attrition rate 22%.
Placebo (n=169). Attrition rate 19%. |
| Outcomes |
weight loss, 10‐year risk of cardiovascular disease based on Framingham model (primary), waist circ, lipid panel, A1c, glucose, blood pressure, HRQL, |
| Notes |
Co‐intervention: diet and exercise counseling. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
